HFpEF management — Research & Evidence

Q: What does the research say about HFpEF management?

The scientific consensus on HFpEF management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims: 0 agreements and 0 contradictions.

Q: What do clinical guidelines recommend for HFpEF management?

Current guideline recommendations: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality. | Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations. | Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L. | Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

What does the research say about HFpEF management?

Emerging pathwayBased on 100 claims (0 agreements, 0 contradictions)

Emerging evidence with 100 primary claims

Journal clubs discussing HFpEF management

Recent sessions

Inflammatory Hypothesis of CAD

STEMI Management — Wed, Aug 12, 8:00 AM EDT — 7 attended

New data on Heart Failure Intervention

Synapse Team — Thu, Jul 16, 4:00 PM EDT

Sessions from public journal clubs on Synapse. RSVP to join the live discussion.

New research on HFpEF management

Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities

European Journal of Heart Failure — Quarta G — Jul 2020

Practical outpatient management of worsening chronic heart failure

European Journal of Heart Failure — Girerd N — Apr 2022

Early pathological mechanisms in a mouse model of heart failure with preserved ejection fraction

American Journal of Physiology-Heart and Circulatory Physiology — Rosas P — Nov 2024

Evidence-based medical therapies for acute heart failure in Cameroon: a retrospective analysis of prescription patterns at Laquintinie Hospital, Douala, 2022–2024

Scientific Reports — Siddikatou D — Oct 2025

Evidence of microvascular dysfunction in heart failure with preserved ejection fraction

Heart — Lee J — Nov 2015

Clinical Studies of Enalapril Treatment for Patients with Severe Congestive Heart Failure.

Japanese Circulation Journal-english Edition — Sato T — Jan 1992

Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction)

European Heart Journal — Linde C — Nov 2010

Heart Failure Patients with Improved Ejection Fraction: Insights from the MECKI Score Database

European Journal of Heart Failure — Agostoni P — Sep 2023

L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease

Journal of Hypertension — Ohtani T — Jul 2012

Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective

Journal of Managed Care & Specialty Pharmacy — Shafrin J — Mar 2025

Heart Failure with Preserved Ejection Fraction in Egypt: An Expert Opinion

Global Heart — Abdelhamid M — Jan 2025

Management of Heart Failure Patient with CKD

Clinical Journal of the American Society of Nephrology — Jan 2021

Stay current on HFpEF management

Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.

Featured authors in HFpEF management

Journal Club takes on HFpEF management

“Statin therapy significantly reduces cardiovascular events in individuals with elevated hs-CRP levels.”
Inflammatory Hypothesis of CADSTEMI Management · Aug 12, 2026

Evidence brief: HFpEF management

HFpEF management (also known as HFpEF, diastolic heart failure, preserved EF). Heart failure with preserved ejection fraction

As of 2026-08-14, the scientific consensus on HFpEF management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

Major professional bodies have published 4 guideline recommendations on HFpEF management. The most-cited include: Class I, Level A: In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality; Class I, Level A: In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations; Class I, Level A: In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L; Class I, Level A: In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hfpef-management.

Deterministic synthesis from Synapse's enriched corpus — 203 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

What do clinical guidelines recommend for HFpEF management?

Class ILOE A

In patients with HFrEF and NYHA class II to III symptoms, the use of ARNi is recommended to reduce morbidity and mortality.

Class ILOE A

In patients with HFrEF, with current or previous symptoms, use of 1 of the 3 beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations.

Class ILOE A

In patients with HFrEF and NYHA class II to IV symptoms, an MRA (spironolactone or eplerenone) is recommended to reduce morbidity and mortality, if eGFR is >30 mL/min/1.73 m2 and serum potassium is <5.0 mEq/L.

Class ILOE A

In patients with symptomatic chronic HFrEF, SGLT2i are recommended to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes.

Follow the latest HFpEF management research

Explore every HFpEF management paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.

Search HFpEF management papers